Title

Anaemia of chronic kidney disease: What we know now

Document Type

Journal Article

Publisher

Codon Publications

School

School of Medical and Health Sciences

RAS ID

23617

Comments

Originally published as: Krishnan, A. R., Trinder, D., Chua, A. C., Chakera, A., Ramm, G. A., & Olynyk, J. K. (2017). Anaemia of chronic kidney disease: What we know now. Journal of Renal and Hepatic Disorders, 1(1), 11-19. Original article available here

Abstract

Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a chronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factors and signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agents that could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators of hepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapies that could be available in the near future targeting the various factors that regulate hepcidin.

DOI

10.15586/jrenhep.2017.5

Access Rights

free_to_read

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

 
COinS